MarginsXMarginsX
Home › Markets › Health Care › ERAS

Erasca Inc. (ERAS)

ERAS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$15.11
-3.51% on the day
Market cap
$5.3B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerERAS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001761918
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
13.1 months
$119.0M cash at September 30, 2026
Share count, 1 year
+23.7%
2025-11-05 to 2026-11-05 · +132.3% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$2.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$119.0M cash; operating cash flow -$27.3M a quarter.Report 2026-09-30
Shares outstanding350,956,416 (2026-11-05); 283,711,805 a year earlier; 151,087,038 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-07-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$51.3M-$32.7M$119.0MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$44.1M-$27.3M$42.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$183.4M-$27.4M$47.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$29.1M-$21.7M$73.8MNo debt tagsNeeds four quarters10-K 2026-03-12
Q3 2025
2025-09-30
Not filed-$30.6M-$21.7M$70.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$33.9M-$20.5M$66.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$31.0M-$31.6M$70.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$32.2M-$24.6M$67.7MNo debt tagsNeeds four quarters10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-07-14
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 357 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.7%
1 month+6.0%
3 months-12.3%
Year to date+321.0%
1 year+516.5%
From 52-week high-30.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MANEVeradermics Incorporated$128.05-1.24%$5.4B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
LQDALiquidia Corporation$56.37-1.81%$5.1B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier